Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
Completed · NCT04076813
Conditions: Myocardial Infarction
At a glance
- Research payments reported, 2025
- $9,400
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 5,050
About the trial
- Sponsor
- Chiesi USA, Inc. (with Duke University)
- Dates
- Started 2019-10-16; completion 2025-12-15
- Results posted
- Not yet
The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.
From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Chiesi USA, Inc. reported $9,400 in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ron Waksman, M.D. Interventional Cardiology · Washington, DC
- Neil J. Wimmer, MD Interventional Cardiology · Newark, DE
- Dominick J. Angiolillo, MD Interventional Cardiology · Jacksonville, FL
- Miguel A. Diaz, MD Interventional Cardiology · Hialeah, FL
- Ajar Kochar, M.D. Interventional Cardiology · Baltimore, MD
- Mir B. Basir, D.O. Interventional Cardiology · Detroit, MI
- Jennifer A. Rymer, M.D., MBA Internal Medicine · Durham, NC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Christiana Hospital, DE $3,530
- Duke University $1,950
- University of Florida $1,400
- Henry Ford Health Hospital, MI $1,000
- Hsa Pgh LLC $800
- Brigham and Women's Hospital, MA $520
- Mhri Pss Team $200
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.